CJ HealthCare Corp. – Product Pipeline Review

Global Markets Direct’s, ‘CJ HealthCare Corp. – Product Pipeline Review – 2016’, provides an overview of the CJ HealthCare Corp.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by CJ HealthCare Corp., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of CJ HealthCare Corp.

The report provides overview of CJ HealthCare Corp. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses CJ HealthCare Corp.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features CJ HealthCare Corp.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate CJ HealthCare Corp.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for CJ HealthCare Corp.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding CJ HealthCare Corp.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

CJ HealthCare Corp. Snapshot 6

CJ HealthCare Corp. Overview 6

Key Information 6

Key Facts 6

CJ HealthCare Corp. - Research and Development Overview 7

Key Therapeutic Areas 7

CJ HealthCare Corp. - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

Pipeline Products - Combination Treatment Modalities 12

Pipeline Products - Partnered Products 13

Partnered Products/Combination Treatment Modalities 14

CJ HealthCare Corp. - Pipeline Products Glance 15

CJ HealthCare Corp. - Late Stage Pipeline Products 15

Pre-Registration Products/Combination Treatment Modalities 15

Phase III Products/Combination Treatment Modalities 16

CJ HealthCare Corp. - Clinical Stage Pipeline Products 17

Phase II Products/Combination Treatment Modalities 17

Phase I Products/Combination Treatment Modalities 18

CJ HealthCare Corp. - Early Stage Pipeline Products 19

IND/CTA Filed Products/Combination Treatment Modalities 19

Preclinical Products/Combination Treatment Modalities 20

Discovery Products/Combination Treatment Modalities 21

CJ HealthCare Corp. - Drug Profiles 22

(ezetimibe + rosuvastatin calcium) 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

(amlodipine besylate + candesartan cilexetil) 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

(amlodipine besylate + rosuvastatin calcium + valsartan) 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

(atorvastatin calcium + metformin hydrochloride) XR 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

tegoprazan 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

CJ-40006 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

darbepoetin alfa 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

(amlodipine besylate + atorvastatin calcium + valsartan) 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

somatropin biobetter 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

NSI-566 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

CJ-14199 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

CJ-40010 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

CJ-40011 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

RQ-00000010 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

RQ-00000774 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Small Molecules to Inhibit Janus Kinase for Rheumatoid Arthritis 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

ranibizumab biosimilar 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

CJ HealthCare Corp. - Pipeline Analysis 40

CJ HealthCare Corp. - Pipeline Products by Target 40

CJ HealthCare Corp. - Pipeline Products by Route of Administration 42

CJ HealthCare Corp. - Pipeline Products by Molecule Type 43

CJ HealthCare Corp. - Pipeline Products by Mechanism of Action 44

CJ HealthCare Corp. - Recent Pipeline Updates 46

CJ HealthCare Corp. - Dormant Projects 55

CJ HealthCare Corp. - Locations And Subsidiaries 56

Head Office 56

Other Locations & Subsidiaries 56

Appendix 57

Methodology 57

Coverage 57

Secondary Research 57

Primary Research 57

Expert Panel Validation 57

Contact Us 57

Disclaimer 58

List of Tables

List of Tables

CJ HealthCare Corp., Key Information 6

CJ HealthCare Corp., Key Facts 6

CJ HealthCare Corp. – Pipeline by Indication, 2016 9

CJ HealthCare Corp. – Pipeline by Stage of Development, 2016 10

CJ HealthCare Corp. – Monotherapy Products in Pipeline, 2016 11

CJ HealthCare Corp. – Combination Treatment Modalities in Pipeline, 2016 12

CJ HealthCare Corp. – Partnered Products in Pipeline, 2016 13

CJ HealthCare Corp. – Partnered Products/ Combination Treatment Modalities, 2016 14

CJ HealthCare Corp. – Pre-Registration, 2016 15

CJ HealthCare Corp. – Phase III, 2016 16

CJ HealthCare Corp. – Phase II, 2016 17

CJ HealthCare Corp. – Phase I, 2016 18

CJ HealthCare Corp. – IND/CTA Filed, 2016 19

CJ HealthCare Corp. – Preclinical, 2016 20

CJ HealthCare Corp. – Discovery, 2016 21

CJ HealthCare Corp. – Pipeline by Target, 2016 41

CJ HealthCare Corp. – Pipeline by Route of Administration, 2016 42

CJ HealthCare Corp. – Pipeline by Molecule Type, 2016 43

CJ HealthCare Corp. – Pipeline Products by Mechanism of Action, 2016 45

CJ HealthCare Corp. – Recent Pipeline Updates, 2016 46

CJ HealthCare Corp. – Dormant Developmental Projects,2016 55

CJ HealthCare Corp., Other Locations 56

List of Figures

List of Figures

CJ HealthCare Corp. – Pipeline by Top 10 Indication, 2016 8

CJ HealthCare Corp. – Pipeline by Stage of Development, 2016 10

CJ HealthCare Corp. – Monotherapy Products in Pipeline, 2016 11

CJ HealthCare Corp. – Combination Treatment Modalities in Pipeline, 2016 12

CJ HealthCare Corp. – Partnered Products in Pipeline, 2016 13

CJ HealthCare Corp. – Pipeline by Top 10 Target, 2016 40

CJ HealthCare Corp. – Pipeline by Route of Administration, 2016 42

CJ HealthCare Corp. – Pipeline by Molecule Type, 2016 43

CJ HealthCare Corp. – Pipeline Products by Top 10 Mechanism of Action, 2016 44

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared